NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Tiziana Life Sciences Ltd. TLSA
9 fiscal years on record · USD · FY2024 reported · SEC filings only
$-11.9M
$-1.5M
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
·
Revenue, FY2024 · full 9-year series below
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
·
ROE
FY2024 · ROE -250.5%
-100%-200%
201620202024
Three returns, three denominators.
Each USD of equity lost 250 cents this year.
The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Income tax $B | −0.0 | 0.0 | ◌ | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | ◌ | ◌ | −0.0 | −0.0 | −0.0 | ◌ | −0.0 | ◌ |
| EPS, diluted $ | −0.11 | −0.17 | −0.15 | −0.24 | −0.16 | ◌ | ◌ | ◌ | ◌ |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — |
| ROE % | −250.5 | −140.9 | −50.6 | −45.2 | −39.6 | −12.8 | — | — | −239.0 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Provenance
Company facts, as filed
How we verify · 3 failures in 34 reconciliationsAUDITED
Reconciled in 6 of the 9 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. Nine checks were skipped: EPS is not tagged before 2016.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency3 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code D0
Fiscal year endsDecember 31
Data on record since2016